Revolution Medicines, Inc. (RVMD)
Valor JustoFundamental
30
Precio
$209.03
Capitalización Bursátil
$43.99B
Parte 1 · Cuánto vale la empresa
Resumen
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
0
Ejercicio cerrado el 31/12/2025
Beneficio Neto
$-1.13B
Ejercicio cerrado el 31/12/2025
Flujo de Caja Libre
$-914M
Patrimonio Neto Total
$1.63B
Pasivo Total
$723M
Ratio de Liquidez
11.38
Cobertura de Intereses
27.42
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
No hay datos de ingresos disponibles
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$257.47
Precio Actual
$209.03
Margen de Seguridad
+18.8%
Rango de Valor Justo
$244.59 - $270.34
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-69.3%
Ratio P/B
16.88
P/FCF
-
Margen Bruto
-
ROIC
-32.4%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
-32.4%
WACC
12.1%
ROIC − WACC
-44.5 pp
El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.
Criterios de Análisis Fundamental
Superado (7)
- EPS shows upward trend
- Price CAGR 29.97%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Analyst Consensus 93% Buy
Fallido (10)
- ROIC -32.4%
- P/B Ratio 16.88
- Operating Margin -Infinity%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -54.1%
- Earnings Surprise avg -25.1%
- Share Dilution 13.4%
- Piotroski F-Score 1/9
No disponible (10)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Dr. Mark A. Goldsmith M.D., Ph.D. | CEO, President & Chairman | 63 |
| Mr. Jack Anders | Chief Financial Officer | 48 |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer | 62 |
| Mr. Jeffrey Cislini J.D. | Senior VP, General Counsel & Corporate Secretary | 50 |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Senior Advisor | 64 |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | - |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | 44 |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | - |
| Mr. Walter Reiher Ph.D. | Chief Information Officer | - |
| Ms. Jan Smith Ph.D. | Chief Scientific Officer | - |
Riesgo de Auditoría
2
Riesgo del Consejo
8
Riesgo de Compensación
8
Riesgo de Derechos del Accionista
8
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-25
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-08-05
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-09-01
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for RVMD, sourced from Markets Gazette.
- 8/27/2026POSITIVERevMed’s Pancreatic Cancer Pill Priced Above $475K per Year
Revolution Medicines has secured US approval for Rasonque, a novel pill targeting advanced pancreatic cancer, a significant breakthrough in treating a notoriously difficult tumor type. The drug, priced at over $475,000 annually, is among the most expensive cancer therapies developed. Its broad targeting of the RAS protein, a key driver in most pancreatic cancers, offers a new therapeutic avenue. This approval marks a substantial advancement in oncology, potentially improving patient outcomes and establishing a new standard of care for this challenging disease.
- 6/1/2026POSITIVERevolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
Revolution Medicines announced a significant breakthrough in pancreatic cancer treatment, with its experimental pill demonstrating a doubling of patient survival rates and a 60% reduction in the risk of death during clinical trials. This development is particularly noteworthy given the historically poor prognosis associated with pancreatic cancer. The positive trial results suggest a potential paradigm shift in treatment options for this aggressive disease. For investors, this news could translate into substantial future revenue streams and a re-evaluation of the company's growth prospects, especially as the stock is currently trading near its all-time highs.
- 4/13/2026POSITIVERevolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo
Revolution Medicines Inc. stock surged following promising Phase 3 trial results for its pancreatic cancer drug, darsonvalrasib. The study demonstrated a doubling of survival rates compared to standard chemotherapy, a significant breakthrough for patients with KRAS G12C-mutated pancreatic cancer. The company announced plans for regulatory filings, signaling a clear path toward potential market approval. This development is highly encouraging for investors, suggesting a strong future revenue stream and a significant advancement in oncology treatment.
- 2/25/2026NEUTRALRevolution Medicines (RVMD) Earnings Transcript
Revolution Medicines (RVMD) has released its earnings transcript, although the specific content is not yet available for analysis. Investors are keenly awaiting the details of this publication, which could provide clarity on the company's financial performance and future outlook. The absence of immediate information prevents a directional assessment, keeping the stock in a holding pattern. It will be crucial to monitor the data as soon as it is disclosed to understand the impact on research and development, product pipeline, and market strategies, which are fundamental elements for evaluating RVMD's growth potential in the biopharmaceutical sector.
via Markets Gazette